Tenax Therapeutics shares are trading lower after the company announced its Phase 3 LEVEL clinical trial evaluating TNX-103 did not meet its primary or key secondary endpoints.

Benzinga Newsdesk www.benzinga.com Negative 97.2%

Neg 97.2% Neu 0% Pos 0%

Comments

No comments yet. Be the first!